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ORIGINAL ARTICLE
Quality of Life and Economic Burden in Recessive 
Dystrophic Epidermolysis Bullosa
In Kyung Jeon, Hye Rang On, Soo-Chan Kim
Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, 
Seoul, Korea
Background: Patients with recessive dystrophic epi-
dermolysis bullosa (RDEB) exhibit blisters and erosions since 
birth, causing pain, pruritus and various complications. 
RDEB affects quality of life (QoL) in physical, emotional and 
social aspects. Furthermore, interminable dressing changes 
and supportive therapies impose a significant economic bur-
den on the patient’s family. Objective: We assessed the QoL 
and economic burden in patients with RDEB. Methods: 
Sixteen patients with RDEB were surveyed to assess the QoL 
and economic burden. Patients answered questionnaires 
consisting of a visual analogue scale (VAS) on pain and pruri-
tus, Skindex-29, Quality of Life in EB questionnaire 
(QOLEB), and the economic burden due to EB. Results: 
Thirteen patients with RDEB completed the questionnaire. 
Female patients presented higher VAS, QOLEB and total 
Skindex-29 scores than male patients. Patients with RDEB 
showed severe levels of pruritus, which was more intoler-
able than pain. Mean VAS score on pain in RDEB was higher 
than in oral lichen planus and post-herpetic neuralgia. VAS 
score on pruritus was similar to those in chronic urticaria, 
atopic dermatitis, and prurigo nodularis. Compared with oth-
er dermatologic conditions, patients with RDEB were pro-
foundly affected in all three scales of skindex-29. Mean 
“medical cost” in a month was $257.54 (USD) (±169.39) 
and mean “dressing cost” was $358.41 (USD) (±312.55), 
which was negatively related to patient age. Conclusion: 
RDEB had a profound impact on QoL and economic burden. 
Compared with other dermatologic diseases, RDEB showed 
severe symptoms and QoL was seriously impaired. Most pa-
tients sustained economic burdens, especially on preparing 
dressing materials. Younger patients experienced more eco-
nomic burdens.
(Ann Dermatol 28(1) 6∼14, 2016)
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INTRODUCTION
Epidermolysis bullosa (EB) encompasses a heterogeneous 
group of inherited skin diseases characterized by blistering 
and erosion of the skin after minor mechanical trauma or 
friction. The four major types of EB are defined according 
to differences in their level of separation within the der-
mal-epidermal junction on electron microscopy and im-
munofluorescence mapping: the epidermis in EB simplex 
(EBS), the lamina lucida in junctional EB (JEB), the sub- 
lamina densa in dystrophic EB (DEB), and mixed in 
Kindler syndrome1.
Recessive DEB (RDEB) is caused by mutations in the 
COL7A1 gene and is inherited in an autosomal recessive 
manner. The two major subtypes of RDEB, generalized se-
vere subtype (RDEB-gen sev), previously called Hallopeau- 
Siemens type, and RDEB generalized intermediate (RDEB- 
gen intermed) subtype, exhibit generalized blistering, nail 
dystrophy, ocular and oral involvement, contractures, se-
vere deformities of the hands and feet, as well as multiple 
extracutaneous impairments1. These physical impairments 
affect the physical, emotional, and social domains of qual-
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ity of life (QoL) in patients with RDEB. Several studies on 
QoL in EB have been reported in the United States, 
Australia, and Italy2-5, meanwhile, studies have yet to eval-
uate QoL in patients with EB throughout Asia. 
Although promising cell-based treatments are under inves-
tigation6,7, treatment of EB mainly relies on supportive 
therapies (e.g., avoiding trauma, wound dressing, and 
management of extracutaneous complications). Neverthe-
less, although interminable dressing changes and suppor-
tive therapies impose a significant economic burden on 
the family members of patients with EB, studies have yet 
to measure the economic burden thereof8. Accordingly, in 
this study, we aimed to assess QoL and costs related to 
treatment in patients with RDEB to obtain a better under-
standing of the overall burden of EB.
MATERIALS AND METHODS
Study design
This cross-sectional, observational study included patients 
with RDEB who were diagnosed at the Department of 
Dermatology, Gangnam Severance Hospital, Seoul, Korea. 
All diagnoses were confirmed by transmission electron mi-
croscopy, immunofluorescence mapping, and mutational 
analysis. The study was approved by the Institutional 
Review Board in Gangnam Severance Hospital (3-2012- 
0028). 
Sixteen patients with RDEB were surveyed for QoL and 
economic burden. Patients were oriented about the ques-
tionnaires, and written consents were obtained before the 
survey. The documents were mailed to the patients who 
were unable to visit. Completed questionnaires and signed 
consent forms were returned by mail. 
Patients answered questionnaires consisting of the visual 
analogue scale (VAS) on pain and pruritus, Skindex-29, 
Quality of Life in EB (QOLEB), and questions addressing 
economic burden of treatment. Information about accom-
panying complications, body surface area (BSA) involved, 
perceived disease severity by patient global assessment 
(PGA), and days of hospitalization because of EB in the 
previous year were also obtained. Accompanying compli-
cations included infection, poor wound healing, anemia, 
nutritional problems, growth retardation, esophageal stric-
ture, constipation, eye lesions, dental problems, urinary 
dysfunction, contractures, nail dystrophy, depression, and 
others. For children under 7-years old, main caregivers 
were asked to participate in the survey to answer the 
questionnaires. 
Measurement tools
1) Visual analogue scale
The VAS has been demonstrated to be a reliable and valid 
method for measuring pain and pruritus9,10. Average de-
grees of daily disease-related pain and pruritus were as-
sessed by a linear 10-score visual analogue scale, ranging 
from 0 (no symptom) to 10 (intolerable symptom). VAS 
scores of RDEB were compared to other dermatologic dis-
eases reported in the literature11-15. VAS differences of 6∼
10 mm were considered as clinically meaningful16.
2) Skindex-29
Skindex-29 is a reliable dermatology-specific instrument to 
measure QoL17. The Korean version of Sindex-29 has been 
translated and has proven value in evaluating QoL for vari-
ous dermatologic diseases18-21. The questionnaire included 
29 questions consisting of three scales (symptom, function-
ing, emotional burden). Patients were requested to answer 
these questions concerning the preceding 4-week period 
using a 5-point scale. (from never=0, to all the time=4). 
In each scale, the score was represented as a percentage 
of the highest score, from 0 to 100; higher values indicate 
a poor QoL. We also compared Skindex-29 scores of 
RDEB with other dermatologic diseases reported in the lit-
erature22.
3) QOLEB questionnaire 
To our knowledge, this is the first disease-specific QoL 
tool for EB, and is a valid and reliable measurement tool 
reflecting the inability of a patient with EB to perform cer-
tain tasks4. Patients were asked to answer 17 questions us-
ing a 4-point scale (from least=0, to most impact=3).
4) Patient global assessment
Subjective disease severity perceived by the patients was 
assessed using PGA, which consists of a 5-point scale 
(from very mild=0, to very severe=4).
5) Economic burden
Average monthly expenses for “dressing costs” and 
“medical costs” were investigated. “Dressing costs” were 
defined as total expenses for preparing dressings, fixing 
materials, topical agents, and medicines used during 
dressing changes. “Medical costs” were defined as other 
expenses due to EB, excluding “dressing costs”. 
6) Dressing burden
To clarify the burden of dressings, additional questions 
were presented: “Do you experience an economic burden 
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Table 1. Basic patient characteristics
Clinical variable Result 
Total case 13
Age (yr) 21.57±17.61
Gender 
  Male 9 (69.2)
  Female 4 (30.8)
Complication 7.77±2.92 (3∼12)
EB subtype
  RDEB-gen sev 7 (53.8)
  RDEB-gen intermed 6 (46.2) 
Area of body surface involved (%)
  ＞30 13 (100)
  10∼30 0 (0)
  ＜10 0 (0)
Hospitalization due to EB in the last year (d)
  ＞7 5 (38.5)
  ≤7 1 (7.7)
  0 7 (53.8)
PGA
  Very severe 11 (84.6)
  Severe 2 (15.4)
  Moderate 0 (0)
  Mild 0 (0)
  Very mild 0 (0)
Values are presented as mean±standard deviation (range) or 
number (%). EB: epidermolysis bullosa, RDEB: recessive dystrophic
EB, RDEB-gen sev: RDEB generalized severe, RDEB-gen intermed:
RDEB generalized intermediate, PGA: perceived disease severity.
Table 2. Quality of life results
Clinical variable
VAS 
QOLEB
Skindex-29
Pain Pruritus Symptom Emotion Function
Total cases (n=13) 6.54±1.56 7.54±2.07 26.62±7.61 86.31±10.38 75.23±15.76 76.69±12.09
Gender
  Male (n=4) 5.75±0.95 6.75±2.63 25.75±8.22 90.00±14.21 65.00±20.94 75.00±17.68
  Female (n=9) 6.88±1.69 7.88±1.83 27.44±7.78 84.67±8.72 79.78±11.51 77.44±10.00
Hospitalization due to EB in the last year (d)
  0 (n=7) 6.57±1.39 7.14±2.27 25.14±7.35 80.71±10.67 79.14±10.38 77.71±12.22
  ≤7 (n=1) 6 10 25 91 94 88
  ＞7 (n=5) 6.60±2.07 7.60±1.82 29.80±8.70 93.20±5.72 66.00±19.02 73.00±12.81
EB subtype
  RDEB-gen sev (n=7) 6.57±1.72 8.00±1.29 30.14±8.82 90.57±8.96 70.29±17.41 79.00±14.19
  RDEB-gen intermed (n=6) 6.50±1.52 7.00±2.76 23.17±3.76 81.33±10.35 81.00±12.57 74.00±9.65
Perceived disease severity 
  Very severe (n=11) 6.54±1.69 7.54±2.25 28±7.82* 86.72±10.39 78.54±13.97 79.54±10.82*
  Severe (n=2) 6.50±0.71 7.50±0.71  21* 84.00±14.14 57.00±15.55 61.00±1.41*
Values are presented as mean±standard deviation. VAS: visual analogue scale, QOLEB: quality of life in EB questionnaire, EB: epi-
dermolysis bullosa, RDEB: recessive dystrophic EB, RDEB-gen sev: RDEB generalized severe, RDEB-gen intermed: RDEB generalized
intermediate. *p＜0.05.
with preparing dressings/fixing materials?”; “How often do 
you change your dressings?”; “How long does it take to 
change your dressings?”; “Are specialized dressings/fixing 
materials better in function than general dressings/fixing 
materials?”; “What is the most important factor when you 
purchase dressings/fixing materials?”. 
Statistical analysis
Results were expressed as mean±standard deviations. 
Statistical analysis was performed using SAS software 
(version 9.1.3; SAS Institute Inc., Cary, NC, USA) using 
Student’s sample t-test, analysis of variance, and Spear-
man’s rank correlation coefficient. p-value＜0.05 was con-
sidered implying statistical significance. 
RESULTS
Among 16 patients invited, 13 (81.3%) completed the 
questionnaires. Uncompleted questionnaires were ex-
cluded from data analysis. 
Patient demographics and subjective disease severity
Basic patient characteristics are summarized in Table 1. 
Three patients were aged below 7 years and their main 
caregivers participated in the survey together. Nine pa-
tients (69.2%) were male and 4 patients (30.8%) were 
female. The mean accompanying numbers of complica-
tions were 7.77±2.92, with a range of 3 to 12. 
According to the EB classification1, 7 patients (53.8%) 
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Fig. 1. Visual analogue scale (VAS) 
in (A) pain and (B) pruritus. VAS 
differences of 6∼10 mm are con-
sidered as clinically meaningful. 
(A) The mean pain scale in reces-
sive dystrophic epidermolysis bul-
losa (RDEB) is higher than in oral 
lichen planus and herpes zoster 
(post-herpetic neuralgia). (B) The 
mean pruritus scale is similar to 
that in chronic urticaria, atopic der-
matitis, and prurigo nodularis.
Table 3. RDEB versus other skin conditions (Skindex-29)
Clinical variable
Sample 
size
Symptom Emotion Function
RDEB  13 86 (10) 75 (16) 77 (12)
Other skin condition22
  Dermatomyositis  22 42 (25) 45 (27) 28 (29)
  Vulvodynia 280 50 (17) 50 (20) 44 (22)
  Psoriasis  44 42 (21) 39 (27) 23 (27)
  Eczema 102 48 (23) 41 (27) 26 (26)
  Acne vulgaris  63 30 (19) 41 (25) 16 (16)
  Alopecia   7 31 (24) 27 (33) 14 (23)
  Rosacea  29 33 (20) 33 (20) 16 (18)
  Without skin disease 107 14 (2)  9 (13) 4 (8)
Values are presented as mean (standard deviation). RDEB: 
recessive dystrophic epidermolysis bullosa.
were RDEB-gen sev, and 6 patients (46.2%) were 
RDEB-gen intermed. All patients had skin lesions involv-
ing more than 30% of BSA. Five patients (38.5%) were 
hospitalized for more than 7 days because of EB in the 
previous year, 1 patient (7.7%) for less than 7 days, and 7 
patients (53.8%) were not hospitalized at all. Eleven pa-
tients (84.6%) perceived their disease as ‘very severe’ and 
2 patients as ‘severe’ (15.4%).
QoL results
1) Visual analogue scale
Table 2 shows the VAS, QOLEB and Skindex-29 scores for 
different clinical variables. Female patients had higher 
VAS scores in pain and pruritus than male patients. 
Compared with RDEB-gen intermed, RDEB-gen sev had 
higher VAS score in pruritus, but had similar VAS scores 
in pain. VAS scores in pain and pruritus were not sig-
nificantly different among hospitalization days or between 
perceived disease severities. Patient age and accompany-
ing complication numbers had no correlation with VAS 
scores in pain or pruritus.
Compared with other dermatologic diseases, the mean 
pain scale was higher than for oral lichen planus and her-
pes zoster (Fig. 1A). The mean pruritus scale was similar 
to that in chronic urticaria, atopic dermatitis, and prurigo 
nodularis (Fig. 1B). 
2) Skindex-29
The mean score was 86.31±10.38 on the symptoms 
scale, 75.23±15.76 in emotions, and 76.69±12.09 in 
functioning (Table 2). Male patients had higher scores in 
symptoms, and female patients presented higher scores in 
emotions and functioning; however, these results were not 
statistically significant. Skindex-29 was not significantly 
different among the hospitalization days or between EB 
subtypes. On the function scale, patients with perceived 
disease severity of ‘very severe’ reported significantly 
higher scores than those with ‘severe’ (p＜0.05). Patient 
age and accompanying complication numbers had no cor-
relation with Skindex-29. Compared with other dermato-
logic conditions, patients with RDEB were profoundly af-
fected in all three scales of Skindex-29 (Table 3).
3) QOLEB
Mean QOLEB score was 26.62±7.61 (Table 2). Higher 
scores were observed for female patients, patients with 
hospitalization days greater than 7 days, and RDEB-gen 
sev subtype; these results were not statistically significant. 
Patients with perceived disease severity of ‘very severe’ re-
ported significantly higher scores than that of ‘severe’ (p
＜0.05). Patient age and accompanying complication 
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Table 4. Economic burden of RDEB patients in a month
Clinical variable
Medical cost 
(USD)
Dressing cost 
(USD)
Total case (n=13) 257.54±169.39 
(93∼465)
358.41±312.55 
(93∼930)
Gender
  Male (n=4) 267.40±229.00 488.30±411.60
  Female (n=9) 253.20±152.70 300.70±266.10
Hospitalization due to EB 
  in the last year (d)
  0 (n=7) 219.21±148.79 273.69±298.32
  ≤7 (n=1) 46.50 93.00
  ＞7 (n=5) 353.40±166.36 503.10±304.21
EB subtype
  RDEB-gen sev (n=7) 298.90±177.80 431.80±299.80
  RDEB-gen intermed 
    (n=6)
209.30±160.40 272.80±332.00
Values are presented as mean±standard deviation (range). RDEB:
recessive dystrophic EB, EB: epidermolysis bullosa, RDEB-gen 
sev: RDEB generalized severe, RDEB-gen intermed: RDEB ge-
neralized intermediate, USD: United States Dollar.
numbers had no correlation with QOLEB. 
4) Economic burden
Table 4 shows the “medical costs” and “dressing costs” for 
different clinical variables. “Dressing costs” were greater 
than “medical costs”: the mean monthly “medical cost” 
was $257.53±169.39 (USD); the mean monthly “dressing 
cost” was $358.41±312.55(USD). The mean monthly to-
tal cost was $615.97±32.09 (USD). Patients with hospital-
ization days greater than 7 days and RDEB-gen sev sub-
type spent more on “medical costs” and “dressing costs” 
than did other patients. “Medical costs” and “dressing 
costs” were negatively related to patient age (Spearman 
rho=−0.68, p=0.01 and Spearman rho=−0.56, p= 
0.049), representing a statistically meaningful correlation. 
Perceived disease severities and accompanying complica-
tion numbers had no correlation with economic burden. 
“Medical costs” and “dressing costs” had no correlation 
with VAS, QOLEB, and Skindex-29.
5) Dressing burden 
Regarding additional questions about the burden of dress-
ings, 7 patients (53.8%) answered that they have experi-
enced an economic burden on dressing materials 
“always”, and 3 (23.1%) answered “often” (Fig. 2A). 
Regarding dressing change frequency, 7 patients (53.8%) 
changed the dressing every day and 4 patients (30.8%) 
changed three times a week (Fig. 2B). Seven patients 
(53.8%) answered that they require 1∼2 hours to change 
the dressings and 4 (30.8%) required less than 1 hour (Fig. 
2C).
Eleven patients (84.6%) answered that specialized dress-
ings are better or much better in function than general 
dressings (Fig. 2D). Price was the most important factor 
(38.5%) when purchasing dressings, followed by pain dur-
ing dressing change (30.8%) (Fig. 2E). Regarding fixing 
materials, 12 patients (92.3%) answered that specialized 
fixing materials are better than general fixing materials 
(Fig. 2F). Price (38.5%) and fixing ability (38.5%) were 
two important factors considered when selecting fixing 
materials (Fig. 2G). 
DISCUSSION
The present study evaluated the QoL and economic bur-
den of patients with RDEB. To our knowledge, this study 
is the first to assess the economic burden of EB and to 
evaluate the QoL of patients with RDEB in Asia. 
The female sex is reportedly correlated with QoL and psy-
chological morbidity8, reported in EB as well as in other 
dermatological diseases5,23. In the present study, female 
patients presented higher VAS, QOLEB, and total Skindex- 
29 scores than male patients. While VAS scores were 
more severe in females, symptom scores on the Skindex- 
29 scale were higher in males. VAS assesses symptoms ac-
cording to severity, whereas Skindex-29 evaluates symp-
toms according to frequency. QOLEB also evaluates pain 
according to frequency. Notwithstanding, Frew et al.4 sug-
gested that VAS is more accurate for actual assessment of 
pain and pruritus. Moreover, VAS is easy and quick to per-
form, and could be useful during consultation of patients 
with for accurate symptom management.
Compared to other dermatologic diseases in the literature, 
the patients with RDEB included in this study suffered 
from more severe pain: VAS scores on pain were higher 
for RDEB than in oral lichen planus and post-herpetic 
neuralgia. Meanwhile, Fine et al.24 reported that severe 
levels of pain were most often seen in JEB-Herlitz type and 
RDEB Hallopeau–Siemens type. However, in the present 
study, VAS scores on pain were similar between 
RDEB-gen intermed and RDEB-gen sev subtypes. Additio-
nally, compared with other dermatologic diseases, pa-
tients with RDEB showed higher Skindex-29 scores in all 
three scales, further reflecting the disease burden of RDEB. 
Compared with a previous survey of patients with EB in 
Italy5, Skindex-29 scale scores for RDEB were higher in 
our study; however, the previous survey seems to have en-
rolled more participants with a milder phenotype than the 
present did: all patients in the present study had skin in-
volvement greater than 30% patients who had more than 
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Fig. 2. Questions and answers about economic burden and dressing materials. (A) Seven patients answer that they experienced economic 
burden on dressing materials “always”, and 3 patients answered “often”. (B) Seven patients change the dressing every day, and 4 
patients change three times a week. (C) Seven patients answer that they require 1∼2 hours to change their dressings, and 4 patients 
answered less than 1 hour. (D) Eleven patients (84.6%) answer that specialized dressings are better or much better in function than 
general dressings. (E) Price is the most important factor when purchasing dressings, followed by pain during dressing change. (F) 
Regarding fixing materials, 12 patients answer that the specialized fixing materials are better than general fixing materials. (G) Price 
and fixing ability are two important factors when selecting fixing materials.
30% skin involvement in the Italian study showed higher 
symptom. Seven scale scores than the other patients in the 
study. Nevertheless, the present study still showed higher 
Skindex-29 scores. This discrepancy could be related to 
different cultural backgrounds concerning symptoms, 
emotions, and social relationships between Asian and 
Western countries.
Pruritus is a common symptom among patients with EB. 
Nevertheless, the etiology of pruritus in these patients is 
unknown. Abnormal chronic skin inflammation, over-
heating caused by dressings, dry skin, healing wounds, 
and weather are potential contributing factors2,25. Pruritus 
has been reported to be the biggest concern of patients 
with EB, followed by pain2. In our study, patients with 
RDEB showed severe pruritus. VAS scores for pruritus 
among patients with RDEB were similar to those for 
chronic urticaria, atopic dermatitis, and prurigo nodularis. 
However, among these, pruritus in EB would be more in-
fluential to QoL, as it usually starts at birth or early child-
hood, lasts the lifetime of the patient, and scarcely shows 
satisfactory responses to medication. 
Herein, we hypothesized that patients with the severe sub-
type, RDEB-gen sev, would show greater impairment in 
QoL than those with other subtypes. However, patients 
with RDEB subtypes showed no significant differences in 
QoL. In a previous report5, Sindex-29 also showed no sig-
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Fig. 2. Continued.
nificant differences between the types or subtypes of EB. 
This could be explained by heterogeneity within the dis-
ease8. Notwithstanding, in our study, other objective in-
dices (hospitalization days, number of accompanying 
complications) also showed no significant differences in 
QoL. Meanwhile, perceived disease severity according to 
patient global assessment was significantly associated with 
QOLEB scores and Skindex-29 scores. Although establish-
ing a causal relationship was not possible in this ob-
servational, cross-sectional study, impairments in daily ac-
tivity and social relationships might have considerable in-
fluence when patients with EB recognize their disease. 
In this study, we also assessed economic burden. Most pa-
tients reported economic burdens related to preparing 
dressing materials. “Dressing costs” were higher than 
“medical costs,” demonstrating that dressings are the main 
cause of economic burdens in patients with RDEB. In the 
present study, patients reported using various kinds of 
general and special dressings/fixing materials. Many stated 
that specialized dressings/fixing materials were better than 
general dressings/fixing materials with regards to func-
tional aspects. Nevertheless, in addition to their functional 
aspects, the price of dressing materials also considerably 
influenced patients’ decisions to purchase one material 
over another. In Korea, specialized dressing materials are 
not covered by insurance, although three sheets of speci-
alized dressings weekly are covered by insurance for pa-
tients with JEB or DEB. Patients with a “rare and incurable 
disease,” including those with RDEB, are responsible for 
10% of their total expenses. For instance, patients with 
RDEB are covered for three sheets of Mepilex lite 
(Mölnlycke Health Care, Göteborg, Sweden) 20×50 cm 
for approximately $14 (USD) weekly. However, total 
monthly “dressing costs” are much more expensive for pa-
tients with RDEB because they usually require numerous 
sheets of dressing material across the whole body. Most 
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patients change the dressings every day or every other 
day, imposing a tremendous economic burden. 
As skin lesions enlarge, higher economic burden from 
dressing materials is incurred. As all participants in this 
study had skin lesions larger than 30%, comparing 
“dressing costs” according to the involved BSA was not 
possible. Moreover, blisters and erosions can occur at any 
area of the skin in patients with EB; therefore, investigating 
accurate area involvement was not feasible. The BSA of 
infants or children is smaller than in adults; thus, they are 
expected to incur lower expenses than adults. Interestin-
gly, however, younger patients in this study accrued more 
“dressing costs” and “medical costs” than those incurred 
by adults. In infancy and early childhood, physical adjust-
ment ability has not developed fully, and self-induced me-
chanical trauma occurs more frequently, making it difficult 
to maintain dressings. Moreover, secondary complications 
due to skin barrier disruptions and immunologic im-
maturity might increase the “medical costs” in younger pa-
tients with RDEB. Furthermore, older patients would be 
expected to have milder phenotypes than others who have 
died from their disease. 
There are several limitations to our study. First, there is the 
potential for selection bias because our study was con-
ducted at a single institute; our sample may not represent 
the general population with EB. Nevertheless, our institute 
is the only institute that can perform laboratory diagnosis 
of EB; almost all patients in Korea with EB are referred to 
our institute. Second, the small sample size of this study 
also acts as a limitation, although incidence of RDEB is 
very low. Third, patients with severe RDEB were over-rep-
resented because these patients are usually referred to our 
institute. Indeed, all patients included in this study had 
skin lesions involving more than 30% of their body sur-
face area and averaged seven complications. Fourthly, the 
main caregivers of children under 7 years old completed 
the questionnaire. Their answers, which cannot be taken 
to represent the actual QoL of the children, were also in-
cluded for analysis. Finally, the potential for recall bias ex-
ists in this questionnaire-based study.
In conclusion, RDEB had a profound impact on QoL and 
economic burden. The present study could help expand 
the understanding of QoL and economic burden asso-
ciated with RDEB, and in turn, better meet the needs of 
patients with this disease.
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